• 1. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 2. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 3. Aluminium coordination complexes in copolymerization reactions of carbon dioxide and epoxides
  Nduka Ikpo,Jenna C. Flogeras,Francesca M. Kerton Dalton Trans., 2013,42, 8998-9006
• 4. Aggregated-fluorescent detection of PFAS with a simple chip
  Cheng Fang,Jinjian Wu,Zahra Sobhani,Md. Al Amin,Youhong Tang Anal. Methods, 2019,11, 163-170
• 5. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzenesulfonamides

Recent Advances in the Study of 1-(4-Bromobenzene)sulfonylhomopiperidine (CAS: 153439-48-6) in Chemical Biology and Pharmaceutical Research

The compound 1-(4-Bromobenzene)sulfonylhomopiperidine (CAS: 153439-48-6) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This sulfonylhomopiperidine derivative has been the subject of several studies aimed at elucidating its biological activity, mechanism of action, and potential as a lead compound in drug development. The presence of the bromobenzene moiety and the sulfonylhomopiperidine scaffold suggests its utility in targeting specific biological pathways, particularly those involving protein-protein interactions and enzyme inhibition.

Recent studies have focused on the synthesis and optimization of 1-(4-Bromobenzene)sulfonylhomopiperidine to enhance its pharmacological properties. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits potent inhibitory activity against certain kinases involved in inflammatory pathways. The researchers employed a combination of computational modeling and in vitro assays to identify the optimal structural modifications that improve binding affinity and selectivity. These findings highlight the compound's potential as a scaffold for developing novel anti-inflammatory agents.

In addition to its kinase inhibitory properties, 1-(4-Bromobenzene)sulfonylhomopiperidine has shown promise in targeting G protein-coupled receptors (GPCRs). A recent preprint on bioRxiv reported that this compound acts as an allosteric modulator of a specific GPCR implicated in neurological disorders. The study utilized high-throughput screening and molecular dynamics simulations to characterize the compound's binding mode and its effects on receptor conformation. These insights could pave the way for the development of new therapeutics for conditions such as Parkinson's disease and schizophrenia.

The pharmacokinetic profile of 1-(4-Bromobenzene)sulfonylhomopiperidine has also been a focus of recent investigations. A 2024 study in Drug Metabolism and Disposition explored the compound's metabolic stability, plasma protein binding, and distribution in rodent models. The results indicated favorable oral bioavailability and brain penetration, making it a viable candidate for central nervous system (CNS) drug development. However, the study also noted the need for further optimization to reduce potential off-target effects and improve metabolic clearance.

Beyond its therapeutic potential, 1-(4-Bromobenzene)sulfonylhomopiperidine has been employed as a chemical probe in basic research. A recent publication in ACS Chemical Biology detailed its use in elucidating the role of sulfonylhydrazone-forming reactions in cellular signaling. The compound's ability to selectively modify cysteine residues in target proteins has provided valuable insights into redox regulation and post-translational modifications. This application underscores the versatility of 153439-48-6 as both a therapeutic candidate and a research tool.

In conclusion, the growing body of research on 1-(4-Bromobenzene)sulfonylhomopiperidine (CAS: 153439-48-6) highlights its multifaceted potential in chemical biology and drug discovery. Its unique structural features, combined with demonstrated activity against kinases and GPCRs, position it as a promising scaffold for further development. Future studies should focus on optimizing its pharmacological properties, elucidating its mechanism of action in greater detail, and exploring its therapeutic applications in preclinical models. As the field advances, this compound is likely to play an increasingly important role in the development of next-generation therapeutics.

• 5339-59-3(N,N-Dibutylbenzenesulfonamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)